VISUfarma Signs European Licensing Deal For YUVEZZI

Lupin's ophthalmic subsidiary VISUfarma has secured an exclusive European licensing agreement for YUVEZZI, a presbyopia treatment, signaling a structured push into specialty ophthalmology across regulated European markets. For supply chain and manufacturing leads managing ophthalmic drug delivery, the deal raises immediate questions around regional batch release requirements, cold-chain logistics, and GMP-compliant fill-finish capacity aligned to EU standards.

The agreement extends VISUfarma's commercial footprint following Lupin's earlier strategic acquisition of the eye-care specialist, a move that positioned the Indian generics major to compete in higher-margin specialty segments. Presbyopia treatments occupy a narrow but technically demanding product category, where formulation stability, sterility assurance, and preservative-free packaging specifications carry significant regulatory weight under EMA frameworks.

For QA directors and regulatory affairs leads, the licensing structure introduces a layer of supply and quality oversight that typically accompanies cross-border specialty deals: technology transfer protocols, qualified person (QP) release obligations, and post-approval change management under ICH Q10 principles will all require alignment between Lupin's manufacturing network and the European licensee's distribution infrastructure.

The ophthalmic segment has drawn increasing attention from Indian pharma groups seeking to diversify beyond oral solid dosage forms, where margin compression and generic competition have intensified. Sterile ophthalmic manufacturing demands a higher compliance baseline, including particulate control, container-closure integrity testing, and process validation documentation that satisfies both 21 CFR Part 211 and EU GMP Annex 1 requirements for sterile medicinal products.

The commercial trajectory of YUVEZZI across European markets will serve as a measurable indicator of VISUfarma's ability to operationalize Lupin's specialty ophthalmology ambitions at scale.

Source: Media4Growth via Indian Pharma Post, 19 August 2026.